Diphtheria Toxin

"Diphtheria Toxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An ADP-ribosylating polypeptide produced by CORYNEBACTERIUM DIPHTHERIAE that causes the signs and symptoms of DIPHTHERIA. It can be broken into two unequal domains: the smaller, catalytic A domain is the lethal moiety and contains MONO(ADP-RIBOSE) TRANSFERASES which transfers ADP RIBOSE to PEPTIDE ELONGATION FACTOR 2 thereby inhibiting protein synthesis; and the larger B domain that is needed for entry into cells.

Descriptor ID	D004167
MeSH Number(s)	D08.811.913.400.725.115.220 D23.946.123.305
Concept/Terms	Diphtheria Toxin Diphtheria Toxin Toxin, Corynebacterium Diphtheriae Corynebacterium Diphtheriae Toxin

Below are MeSH descriptors whose meaning is more general than "Diphtheria Toxin".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Glycosyltransferases [D08.811.913.400]
Pentosyltransferases [D08.811.913.400.725]
ADP Ribose Transferases [D08.811.913.400.725.115]
Diphtheria Toxin [D08.811.913.400.725.115.220]
Biological Factors [D23]
Toxins, Biological [D23.946]
Bacterial Toxins [D23.946.123]
Diphtheria Toxin [D23.946.123.305]

Below are MeSH descriptors whose meaning is related to "Diphtheria Toxin".

Below are MeSH descriptors whose meaning is more specific than "Diphtheria Toxin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Diphtheria Toxin" by people in this website by year, and whether "Diphtheria Toxin" was a major or minor topic of these publications.

Bar chart showing 8 publications over 6 distinct years, with a maximum of 3 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2005	1	0	1
2007	3	0	3
2008	1	0	1
2009	1	0	1
2012	1	0	1

Below are the most recent publications written about "Diphtheria Toxin" by people in Profiles.

Peng W, Dunton C, Holtz D, Parva M, Stampler K, Forwood M, Gogoi R, Lace MJ, Anderson DG, Sawicki JA. DNA nanotherapy for pre-neoplastic cervical lesions. Gynecol Oncol. 2013 Jan; 128(1):101-106.

View in: PubMed
Phillips SM, Bhopale MK, Hilliard B, Zekavat SA, Ali MA, Rostami A. Suppression of murine experimental autoimmune encephalomyelitis by interleukin-2 receptor targeted fusion toxin, DAB(389)IL-2. Cell Immunol. 2010; 261(2):144-52.

View in: PubMed
Showalter SL, Huang YH, Witkiewicz A, Costantino CL, Yeo CJ, Green JJ, Langer R, Anderson DG, Sawicki JA, Brody JR. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther. 2008 Oct; 7(10):1584-90.

View in: PubMed
Phillips SM, Bhopale MK, Constantinescu CS, Ciric B, Hilliard B, Ventura E, Lavi E, Rostami A. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. J Neurol Sci. 2007 Dec 15; 263(1-2):59-69.

View in: PubMed
Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.

View in: PubMed
Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47.

View in: PubMed
Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH, Flomenberg N, Selby G, Lemaistre CF. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Mar; 11(3):188-93.

View in: PubMed
Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement